| [1] |
LU Mengjie, LIU Yuxiu, LU Guangming, ZHANG Longjiang, HUANG Wei, GE Aichen.
Sample size calculation for single-arm OPC trials with multi endpoints
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(8): 917-921.
|
| [2] |
LI Yun, LI Bingsheng, ZHANG Weifang, LI Yixiu, LI Chun, PENG Juan, LAI Xin, ZHU Jing, XU Ruilai, XIONG Aizhen.
Association study of miR-146a G>C polymorphisms with susceptibility of hepatocellular carcinoma in the Chinese population: a Meta-analysis
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(7): 779-786.
|
| [3] |
.
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2000, 5(3): 279-283.
|
| [4] |
.
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2000, 5(2): 164-165.
|
| [5] |
.
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 1999, 4(3): 220-223.
|
| [6] |
.
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 1999, 4(3): 226-228.
|
| [7] |
.
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 1996, 1(2): 131-135.
|
| [8] |
.
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 1996, 1(2): 136-141.
|
| [9] |
.
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 1996, 1(2): 142-145.
|
